Medical software company Analytical Research Systems, Inc. (ASR) and the University of Colorado recently announced that ASR has an exclusive license for the software developed at the university. ASR will use the technology to further develop a new electronic medical record product “asrSynapse ™” to help small to medium-sized independent physician practices.
The web-based point-of-care tool will provide for a longitudinal electronic health record for patients but with a specific focus on primary care, internal, medicine, and chronic disease management. Advanced informatics will provide quality data analysis, along with patient and practice alerts.
To contact ASR, email David M. Spiegel at support@asrsynapse.com or call (303) 399-6977.
In a second venture involving the University of Colorado, Illumasonix, LLC, an early stage medical device company has executed an exclusive license with the university. The device developed uses both ultrasound and FDA approved microbubbles to track blood flow, provides real-time assessment of blood flow, and detects blockages.
Illumasonix reports that positive initial results were obtained in early 2009 from the ongoing human feasibility study of the technology and the company anticipates that their first product offering could reach the market as early as 2011.
Illumasonx was formed in 2007, as a partnership between University of Colorado and Allied Minds, an investment corporation specializing in early stage university business ventures. The company received undisclosed initial capitalization and research funding from Allied Minds, as well as $250K in matching funds from the State of Colorado.
To find out more details on this project, email Erick Rabins at Erick.rabins@alliedminds.com or call (206) 336-9707.
The third venture involves the University of Colorado and Biotricity Medical Inc. They have recently executed an option agreement allowing Biotricity Medical to develop technology for implantable biogenerators. These biogenerators can provide a long-term potentially inexhaustible power supply for implanted medical devices such as pacemakers, insulin pumps, cochlear implants, and artificial retinas. The potential for the device is also to improve the quality of life for people enduring chronic pain and Parkinson’s disease.
The company’s first planned product EpiVolt™ is made of living electricity generating cells that use the body’s own natural chemicals and processes to create electrical power. This source of power will be much smaller than the batteries it will replace. The device can be implanted in very small spaces along with the device that it powers without the need for long connecting wires running through the body to a remote battery power source.
To find out more details on EpiVolt™, email Dr. Stephen Rathmill at scrathmill@verizon.net or call (508) 497-3988.
For more information on all of the tech transfer projects, email Lindsay Polak at the University of Colorado, Office of Technology Transfer Lindsay.polak@cu.edu or call (303) 735-5518.
